A method is provided for preparing a catecholamine-based compound by using plasma polymerization, and more specifically, to a method for artificially synthesizing various catecholamines, that is, monomolecular compounds capable of having a hydroxyl group (OH) as an ortho group of a benzene ring and various alkylamines as a para group thereof from a catecholamine precursor material such as phenol or aniline by using dry plasma polymerization.

A method is provided for preparing a catecholamine-based compound by using plasma polymerization, and more specifically, to a method for artificially synthesizing various catecholamines, that is, monomolecular compounds capable of having a hydroxyl group (OH) as an ortho group of a benzene ring and various alkylamines as a para group thereof from a catecholamine precursor material such as phenol or aniline by using dry plasma polymerization.

The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.

The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC (()-trans-.sup.9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present disclosure relates to compounds of Formula I that exhibit 5-HT.sub.2A receptor agonist activity and low 5HT.sub.2B receptor agonist activity or deemed 5HT.sub.2B receptor agonist inactivity. In at least some cases, such compounds show selectivity for the 5-HT.sub.2A receptor over the 5-HT.sub.2C receptor. As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders including depression, drug (e.g. tobacco, opiate, and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

The present disclosure relates to compounds of Formula I that exhibit 5-HT.sub.2A receptor agonist activity and low 5HT.sub.2B receptor agonist activity or deemed 5HT.sub.2B receptor agonist inactivity. In at least some cases, such compounds show selectivity for the 5-HT.sub.2A receptor over the 5-HT.sub.2C receptor. As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders including depression, drug (e.g. tobacco, opiate, and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC (()-trans-.sup.9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.

The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.